Dr. Yonaton Zarbiv - Hadassah Cancer Research Institute

Dr. Yonaton Zarbiv MD,

Dr. Yonaton Zarbiv joined the HCRI in 2022, after completing his Oncology residency at Hadassah University Medical Center. Working in the lab of Dr. Albert Grinshpun, he and another research students are researching Urinary cfDNA as a novel biomarker in patients with bladder cancer (metastatic urothelial carcinoma harboring FGFR3 mutations) and being treated with the FGFR inhibitor erdafitinib. Additionally, Yonatan works as a sub-investigator in a number of clinical trials in Hadassah’s Oncology Department.
Dr. Yonaton Zarbiv lectures actively in the Hebrew University Medical School, Oncology Rotation and also in the School of Nursing. He was the Chief Resident in the Department of Oncology, Hadassah University Medical School (2021-2022) and is a member of the Israeli Society Of Clinical Oncology and Radiotherapy.

Breast Cancer with Low Recurrence Score on Oncotype DX©: Interplay Between Early Recurrence, Lobular Histology and BRCA Mutation. Oncology and Therapy, 2022. Yonaton Zarbiv, Yael Berner Wygoda, Albert Grinshpun, Tamar Hamburger, Tamar Sella, Shani Breuer, Ofra Maimon, Yakir Rottenberg, Tamar Peretz & Luna Kadouri
Real‐world Israeli single institution experience with PET‐PSMA for staging of patients with clinically staged localized prostate carcinoma. Cancer Reports, 2021. Yonaton Zarbiv, Yehudit Peerless, Marc Wygoda, Marina Orevi, Karen Meir, Ofer N. Gofrit, Vladimir Yutkin and Stephen Frank
α-Synuclein expression selectively affects tumorigenesis in mice modeling Parkinson’s disease. PLoS One, 2011; Israeli E, Yakunin E, Zarbiv Y, Hacohen-Solovich A, Kisos H, Loeb V, Lichtenstein M, Ben-Gedalya T, Sabag O, Pikarsky E, Lorberboum-Galski H, Sharon R.
Photobiomodulation as an Adjunctive Treatment to Physiotherapy for Reduction of Anterior Knee Pain in Combat Soldiers: A Prospective, Double-Blind, Randomized, Pragmatic, Sham-Controlled Trial. Lasers in Surgery & Medicine, 2021; Gavish L, Spitzer E, Friedman I, Lowe J, Folk N, Zarbiv Y, Gelman E, Vishnevski L, Fatale E, Herman M, Gofshtein R, Gam A, Gertz SD, Eisenkraft A, Barzilay Y.
Beyond KRAS: practical molecular targets in pancreatic adenocarcinoma. Case Reports in Oncology, 2019. Albert Grinshpun, Yonaton Zarbiv, Jason Roszik, Vivek Subbiah and Ayala Hubert.